Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEMECAN Oktonia Typ1
- Development stage
- Unknown
- Lead developer
- DEMECAN
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Sublingual
01
Overview
DEMECAN Oktonia Typ1 is a line of full-spectrum medical cannabis extracts (Vollextrakte) developed by DEMECAN (Deutsche Medizinalcannabis). These extracts are derived from Indica-dominant cannabis cultivars (such as Bubba Kush or Northern Lights) grown in Germany under strict GACP and GMP standards. The Oktonia Typ1 line is designed primarily for evening or nighttime use due to its calming and sedative properties. It is available in various THC:CBD ratios (including 30:1, 25:1, 20:20, 10:10, and 5:20) formulated in a medium-chain triglyceride (MCT) carrier oil. The therapeutic effects are mediated by the active cannabinoids, primarily tetrahydrocannabinol (THC) and cannabidiol (CBD), which act on the endocannabinoid system to alleviate symptoms such as chronic pain, sleep disorders, and anxiety.
- Brand names
- DEMECAN Oktonia Typ 1DEMECAN Oktonia Typ1
- Other names
- DEMECAN ONEDEMECAN Oktonia Typ 1 05:20DEMECAN Oktonia Typ 1 10:10DEMECAN Oktonia Typ 1 20:20DEMECAN Oktonia Typ 1 25:01DEMECAN Oktonia Typ 1 30:01DEMECAN Oktonia Typ1 05:20DEMECAN Oktonia Typ1 10:10DEMECAN Oktonia Typ1 20:20DEMECAN Oktonia Typ1 25:01DEMECAN Oktonia Typ1 30:01Oktonia Typ 1Oktonia Typ1
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on DEMECAN Oktonia Typ1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEMECAN Oktonia Typ1.